PDCD1 and prostate cancer: Thus, these data suggest that prostate cancer resistance to PD-1/PD-L1-targeted CPI is primarily due to immunosuppression of antitumor cytotoxic T cells and can be overcome by increasing the capacity for the immune system to mount an antitumor response, either through increased tumor immunogenicity or increased abundance of tumor-reactive T cells.